1Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Korea.
Clin Appl Thromb Hemost. 2014 May;20(4):442-7. doi: 10.1177/1076029613497424. Epub 2013 Jul 26.
Coagulation and anticoagulation systems are good targets of antiphospholipid antibodies. We assessed the contribution of the antiphospholipid antibodies to the thrombotic risk.
Enzyme-linked immunosorbent assays on antibodies against phosphatidylserine and prothrombin (PS/PT), protein C, protein S, protein Z, and thrombomodulin were performed in 164 patients who showed positive results for lupus anticoagulant or anticardiolipin antibody.
Anti-β-2-glycoprotein I (β2GPI) and anti-PS/PT were significant risk factors for thrombotic events (P < .001, P = .049). However, there was no association between antiprotein C, antiprotein S, antiprotein Z, or antithrombomodulin and thrombosis. Coexistence of anti-β2GPI and anti-PS/PT antibodies was significantly associated with thrombotic events (P = .001). Interestingly, the absence of both anti-β2GPI and anti-PS/PT antibodies was a significant preventive factor for thrombosis (P = .003).
Our data show a lack of association of antiprotein C, antiprotein S, antiprotein Z, and antithrombomodulin antibodies with thrombosis. However, the combination of conventional anti-β2GPI with anti-PS/PT antibody is expected to enhance the predicting power of thrombotic risk.
凝血和抗凝系统是抗磷脂抗体的良好靶点。我们评估了抗磷脂抗体对血栓形成风险的贡献。
对 164 例狼疮抗凝物或抗心磷脂抗体阳性的患者进行了针对磷脂酰丝氨酸和凝血酶原（PS/PT）、蛋白 C、蛋白 S、蛋白 Z 和血栓调节蛋白的抗体酶联免疫吸附试验。
抗β-2-糖蛋白 I（β2GPI）和抗 PS/PT 是血栓事件的显著危险因素（P <.001，P =.049）。然而，抗蛋白 C、抗蛋白 S、抗蛋白 Z 或抗血栓调节蛋白与血栓之间没有关联。抗β2GPI 和抗 PS/PT 抗体的共存与血栓事件显著相关（P =.001）。有趣的是，同时缺乏抗β2GPI 和抗 PS/PT 抗体是血栓形成的显著预防因素（P =.003）。
我们的数据显示，抗蛋白 C、抗蛋白 S、抗蛋白 Z 和抗血栓调节蛋白抗体与血栓形成无关。然而，将传统的抗β2GPI 与抗 PS/PT 抗体相结合，有望提高血栓风险的预测能力。
